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Dramatically increased occurrence of both superficial and invasive fungal infections has been 
observed. Candida albicans appear to be the main etiological agent of invasive fungal infections. 
The anti-C. albicans activity of thiosemicarbazide, 1,3,4-Thiadiazole, and 1,2,4-triazole-3(4H)-thione 
compounds (compounds 3-23) were investigated. The MIC values of thiadiazole and triazole derivatives 
10-23 were in the range of 0.08-0.17 µmol mL-1, while that of fluconazole was 0.052 µmol mL-1. 
Compound 11 (5-(2-(4-chlorobenzyloxy)phenyl)-N-allyl-1,3,4-thiadiazol-2-amine) and compound 18 
(5-(2-(4-chlorobenzyloxy)phenyl)-4-allyl-2H-1,2,4-triazole-3(4H)-thione) were found to be the most 
active compounds, with MIC values of 0.08 µmol mL-1. The newly synthesized thiadiazole and triazole 
compounds (compounds 10-23) showed promising anti-Candida activity. The allyl substituent-bearing 
compounds 11 and 18 exhibited significant anti-Candida albicans activity and showed a binding mode 
as well as the fluconazole x-ray structure. 
Uniterms: Anti-Candida/docking studies. Thiadiazole. Triazole. 
INTRODUCTION
Over the last two decades, dramatically increased 
occurrence of both superficial and invasive fungal 
infections has been observed. In organ transplant cases and 
in immune compromised individuals, including patients 
with cancer or AIDS, fungal infections are the major 
cause of morbidity and mortality (Romani, 2008). The 
invasive Candida infections are mainly caused by Candida 
albicans and account for 30-40% of fungal infection-
related mortality (Pfaller, Diekema, 2010). 
A major obstacle in the treatment of Candida 
infections is the spread of anti-Candida drug resistance 
following long-term regular administration of antimycotic 
therapy in severely immunocompromised subjects, such 
as cancer patients, transplant recipients, and patients 
undergoing surgery. In spite of the development of new 
drugs, such as new azole or echinocandin derivatives, 
there has been a dramatic increase in both anti-Candida 
resistance and the frequency of invasive Candida 
infections (Pfaller, 2012). Among enormous classes of 
heterocyclic compounds, the synthesis of new derivatives 
of 1,2,4-triazole-3-thiones and 2-amino-1,3,4-thiadiazoles 
has been attracting considerable attention because of 
their broad biological activity, including antibacterial and 
antifungal (Güzeldemirci, Küçükbasmaci, 2010; Plec et 
al., 2011; Camoutsis et al., 2010; Küçükgüzel et al., 2007; 
Kadi et al., 2007), anti-tubercular (Küçükgüzel et al., 2001; 
Küçükgüzel et al., 2008), antiviral (Abdel-Aal et al., 2003; 
Küçükgüzel et al., 2008), antioxidant (Ayhan-Kilcigil et 
al., 2004; Khan et al., 2010), antitumoral (Duran, Dogan, 
Rollas, 2002; Rzeski, Matysiak, Kandefer-Szerszen, 2007; 
Mavrova et al., 2009), anti-inflammatory (Amir, Shikha, 
2004; Kadi et al., 2007; Küçükgüzel et al., 2007; Kumar et 
al., 2008), and anticonvulsant activity (Kane et al., 1994; 
Sharma et al., 2011; Dogan et al., 2002). Clinically-used 
antifungal azole drugs containing either an imidazole (e.g., 
econazole, miconazole, clotrimazole, and ketoconazole) or 
a 1,2,4-triazole moiety (e.g., fluconazole and itraconazole) 
have a high therapeutic index and significant safety 
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profile (Wang et al., 2009). Azoles were broadly used as 
first-line treatment of invasive fungal infections, which 
led to the emergence of high resistance (Hoffman, Ernst, 
Klepser, 2000; Casalinuovo, Di Francesco, Garaci, 2004) 
that largely decreased their efficacy. Azoles exert their 
antifungal activity by inhibiting the synthesis of sterols in 
fungal cells. This may be achieved through its inhibitory 
effect on cytochrome P450-dependent 14a-lanosterol 
demethylase, exerted through binding to the heme cofactor 
of the cytochrome CYP51”. (Odds, Brown, Gow, 2003; 
Hamdan, Hahn, 2006). As a result, ergosterol is depleted, 
and subsequent accumulation of lanosterol inside the fungal 
cells occurs, leading to inhibition of their growth. Because 
of the vital role of the CYP51 enzyme in the biosynthetic 
processes of fungal cells, CYP51 is considered the main 
target of antifungal azole agents (Lamb et al., 1999). In 
view of the potential biological activity of derivatives of 
1,2,4-triazole and 1,3,4-thiadiazole and in continuation of 
our ongoing research on the synthesis of heterocycles with 
potential antimicrobial activity (Radwan, Hussein, 2006; 
Mostafa et al., 2008; Aboul-Fadl et al., 2012; Attia et al., 
2013; Radwan, 2013; Ghorab et al., 2013a, b; Radwan et 
al., 2014; Radwan, Abdel-Mageed, 2014), we synthesized 
a new series from 1,2,4-triazole and 1,3,4-thiadiazole in 
order to examine their antifungal activity. Hydrocarbon 
substituents with variable size were included at position 2 
of the thiadiazole ring and at position 1 of the triazole ring 
in order to enhance the lipophilicity and subsequently the 
biological activity of the compounds and to study the steric 
and electronic effect of these substituents on biological 
activity.
MATERIAL AND METHODS
Methyl salicylate (1), chlorobenzyl chloride 
(2), and isothiocyanate derivatives were purchased 
from Sigma-Aldrich Company (St. Louis, MO, USA). 
Measurements of melting points were done on a Barnstead 
9001 Electrothermal apparatus using open capillary tubes; 
these measurements were uncorrected. FTIR spectra 
were obtained using KBr discs on a Perkin-Elmer (USA) 
spectrophotometer at the research center of the College of 
Pharmacy, King Saud University, Saudi Arabia. 1H and 13C 
NMR spectra were recorded in DMSO-d6 on a Bruker NMR 
spectrophotometer operating at either 500 MHz or 125.76 
MHz. Elemental analysis was performed on a Perkin-Elmer 
CHNSO analyzer, model no. 2400. Reaction monitoring 
and purity testing of the final products were carried out by 
thin layer chromatography (TLC) using silica gel-precoated 
aluminum sheets (60 F254, Merck) and visualization with 
ultraviolet light (UV) at 365 and 254 nm.
Synthesis of methyl 2-(4-chlorobenzyloxy)
benzoate (1)
Methyl 2-hydroxybenzoate (1.3 g, 0.01 mol) 
was dissolved in dry acetone (120 mL). Dry potassium 
carbonate (4.14 g, 0.03 mol) was added and the mixture 
was stirred at room temperature for 10 min. Chlorobenzyl 
chloride (3.86 mL, 0.03 mol) was added to the mixture 
and the solution was heated under reflux for 18 h under 
a nitrogen atmosphere. The cooled reaction mixture was 
filtered, the solvent was removed under reduced pressure, 
and the residue was dissolved in dichloromethane (25 
mL). The organic layer was washed consecutively 
with 5% aqueous NaOH (25 mL), brine (20 mL), and 
distilled water (20 mL). The organic layer was dried over 
magnesium sulfate and the solvent was removed under 
reduced pressure. The residue was purified by column 
chromatography with 5%-20% ethyl acetate/hexane as 
eluent to afford the product. Yield 2.5 g, 90%.
Synthesis of 2-(4-chlorobenzyloxy)
benzohydrazide (2)
Methyl 2-(4-chlorobenzyloxy)benzoate (1) (2.76 g, 
0.01 mol), ethanol (20 mL), and 64% hydrazine hydrate 
(4 mL) were mixed together and heated under reflux 
at 80°C for 8 h. TLC eluted with 1:4 ethanol/benzene 
showed the development of a new spot at Rf = 0.65. 
Ethanol was evaporated under reduced pressure and a 
white solid product was recrystallized from H2O/MeOH 
to yield compound 2 (2.6 g, 95% yield), melting point 
111-112°C, IR (KBr, cm-1) 3246 (NH), 1583 (CO-N). 
1H NMR (DMSOd6, δ ppm): 4.53 (s, 2H, NH2), 5.24 (s, 
2H, Ar–CH2–O), 7.02–7.65 (8H, m, Ar-Hs), 9.24 (s, 1H, 
-CONH). 13C NMR (DMSO-d6, δ ppm): 69.4 (Ar–CH2–O), 
113.82, 121.27, 123.38, 128.97, 129.81, 130.18, 132.12, 
132.94, 136.3, 156.97 (C-Ar), 165.54 (C=O). Anal. calcd. 
for C14H13ClN2O2: C, 60.77; H, 4.74; N, 10.12. Found: C, 
60.63; H, 4.85; N, 10.01.
Synthesis of 1-(2-(4-chlorobenzyloxy)benzoyl)-4-
substituted-thiosemicarbazide (3-9)
T h e  c o m p o u n d  2 - ( 4 - c h l o r o b e n z y l o x y )
benzohydrazide (2) (2.76 g, 0.01 mol) was dissolved in 
absolute ethanol (20 mL). The isothiocyanate reagents 
(0.011 mol) were separately dissolved in absolute ethanol 
(10 mL). Then, the solution of isothiocyanate was poured 
into the solution of hydrazide, with continuous stirring. 
The reaction mixture was refluxed for 2 h, and then cooled 
to room temperature. The crude solid was then filtered 
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and recrystallized from appropriate solvent to yield 
compounds 3-9.
1-(2-(4-chlorobenzyloxy)benzoyl)-4-
phenylthiosemicarbazide (3)
Yield 4.02 g, 98%, melting point 176–178 °C; IR 
(KBr) 3320, 1664, 1618, 833, 750, 691 cm-1; 1H NMR 
(DMSOd6, δ ppm): 5.32 (2H, s, (Ar–CH2–O), 7.08–7.87 
(13H, m, Ar-Hs), 9.42, 9.93, 10.15 (3s, 3H, 3NH). 13C 
NMR (DMSO-d6, δ ppm): 69.69 (Ar–CH2–O), 114.05, 
121.4, 122.1, 123.4, 125.2, 126.4, 128.63, 128.09, 
130.1, 131.22, 133.07, 133.25, 135.93, 139.48, 156.38 
(C-Ar), 165.15 (C=O), 182.23 (C=S). Anal. calcd. for 
C21H18ClN3O2S: C, 61.23; H, 4.40; N, 10.20; S, 7.78. 
Found: C, 61.01; H, 4.58; N, 10.03; S, 7.63.
1-(2-(4-chlorobenzyloxy)benzoyl)-4-
allylthiosemicarbazide (4)
Yield 3.2 g, 85%, melting point 157–158 °C; 
IR (KBr) 3314, 1648, 1622, 852, 772, 672 cm-1; 1H 
NMR (DMSOd6, δ ppm): 4.04 (s, 2H, CH2=CH-CH2-), 
5.07 (d, 1H, J=10, transCH2=CH-), 5.11 (d, 1H, J=17, 
cisCH2=CH-), 5.28 (s, 2H, Ar–CH2–O), 5.79 (m, 1H, 
CH2=CH-CH2-), 7.06–7.97 (8H, m, Ar-Hs), 9.37, 9.71, 
10.09 (3s, 3H, 3NH). 13C NMR (DMSO-d6, δ ppm): 46.19 
(allyl-CH2), 69.57 (Ar–CH2–O), 113.93, 119.71, 121.32, 
128.95, 130.05, 131.03, 133.03, 133.05, 135.01, 136.05, 
156.26 (C-Ar), 165.02 (C=O), 181.95 (C=S). Anal. calcd. 
for C18H18ClN3O2S: C, 57.52; H, 4.83; N, 11.18; S, 8.53. 
Found: C, 57.43; H, 4.91; N, 11.03; S, 8.61.
1-(2-(4-chlorobenzyloxy)benzoyl)-4-(m-tolyl)
thiosemicarbazide (5)
Yield 4.08 g, 96%, melting point 170–171 °C; IR 
(KBr) 3294, 1640, 1608, 816, 746, 694 cm-1; 1H NMR 
(DMSOd6, δ ppm): 2.28 (s, 3H, CH3), 5.31 (s, 2H, Ar–
CH2–O), 6.96–7.86 (m, 12H, Ar-Hs), 9.36, 9.82, 10.18 
(3s, 3H, 3NH). 13C NMR (DMSO-d6, δ ppm): 21.44 (CH3), 
69.7 (Ar–CH2–O), 114.04, 121.42, 125.05, 128.45, 128.89, 
130.08, 131.18, 133.07, 133.23, 135.91, 139.32, 156.37 
(C-Ar), 165.23 (C=O), 180.76 (C=S). Anal. calcd. for 
C22H20ClN3O2S: C, 62.04; H, 4.73; N, 9.87; S, 7.53. Found: 
C, 61.92; H, 4.80; N, 9.76; S, 7.38.
1-(2-(4-chlorobenzyloxy)benzoyl)-4-(p-tolyl)
thiosemicarbazide (6)
Yield 4.16 g, 98%, melting point 162–163 °C; IR 
(KBr) 3294, 1640, 1608, 816, 746, 694 cm-1; 1H NMR 
(DMSOd6, δ ppm): 2.29 (s, 3H, CH3), 5.31 (s, 2H, Ar–
CH2–O), 7.07–7.86 (m, 12H, Ar-Hs), 9.42, 9.88, 10.12 
(3s, 3H, 3NH). 13C NMR (DMSO-d6, δ ppm): 21.01 
(CH3), 69.69 (Ar–CH2–O), 114.03, 121.4, 128.89, 129.14, 
130.09, 131.19, 133.08, 133.21, 135.91, 136.85, 156.37 
(C-Ar), 165.78 (C=O), 180.93 (C=S). Anal. calcd. for 
C22H20ClN3O2S: C, 62.04; H, 4.73; N, 9.87; S, 7.53. Found: 
C, 61.88; H, 4.79; N, 9.93; S, 7.61.
1-(2-(4-chlorobenzyloxy)benzoyl)-4-(o-tolyl)
thiosemicarbazide (7)
Yield 4.0 g, 95%, melting point 148–149 °C; IR 
(KBr) 3323, 1662, 1628, 869, 772, 732 cm-1; 1H NMR 
(DMSOd6, δ ppm): 2.14 (s, 3H, CH3), 5.24 (s, 2H, Ar–
CH2–O), 7.07–7.85 (m, 12H, Ar-Hs), 9.15, 9.72, 10.16 
(3s, 3H, 3NH). 13C NMR (DMSO-d6, δ ppm): 18.06 (CH3), 
69.69 (Ar–CH2–O), 113.93, 121.32, 126.26, 126.97, 
128.87, 130.04, 130.53, 131.13, 133.06, 135.87, 156.35 
(C-Ar), 165.62 (C=O), 181.06 (C=S). Anal. calcd. for 
C22H20ClN3O2S: C, 62.04; H, 4.73; N, 9.87; S, 7.53. Found: 
C, 62.14; H, 4.8; N, 9.75; S, 7.46.
1-(2-(4-chlorobenzyloxy)benzoyl)-4-(3-chlorophenyl)
thiosemicarbazide (8)
Yield 4.35 g, 98%, melting point 151–152 °C; IR 
(KBr) 3314, 1683, 1612, 876, 778, 674 cm-1; 1H NMR 
(DMSOd6, δ ppm): 5.24 (s, 2H, Ar–CH2–O), 7.08–7.87 
(m, 12H, Ar-Hs), 9.52, 10.04, 10.14 (3s, 3H, 3NH). 13C 
NMR (DMSO-d6, δ ppm): 69.67 (Ar–CH2–O), 114.06, 
121.4, 124.98, 128.88, 129.81, 130.05, 131.27, 132.62, 
133.07, 133.32, 135.92, 141.06, 156.43 (C-Ar), 165.3 
(C=O), 181.58 (C=S). Anal. calcd. for C21H17Cl2N3O2S: 
C, 56.51; H, 3.84; N, 9.41; S, 7.18. Found: C, 56.43; H, 
3.71; N, 9.52; S, 7.25.
1-(2-(4-chlorobenzyloxy)benzoyl)-4-
isopropylthiosemicarbazide (9)
Yield 3.54 g, 94%, melting point 163–164 °C; IR 
(KBr) 3335, 1672, 1628, 853, 764, 679 cm-1; 1H NMR 
(DMSOd6, δ ppm): 1.06 (d, 6H, J=6, 2CH3), 4.35 (m, 1H, 
CH), 5.31 (s, 2H, Ar–CH2–O), 7.06–7.75 (m, 8H, Ar-Hs), 
9.25, 9.48, 10.12 (3s, 3H, 3NH). 13C NMR (DMSO-d6, 
δ ppm): 22.34 (CH3), 46.01 (>CH), 69.61 (Ar–CH2–O), 
113.97, 118.32, 121.4, 127.81, 128.97, 129.82, 129.25, 
133.04, 133.08, 156.06 (C-Ar), 165.1 (C=O), 180.52 
(C=S). Anal. calcd. for C18H20ClN3O2S: C, 57.21; H, 5.33; 
N, 11.12; S, 8.49. Found: C, 57.08; H, 5.41; N, 11.19; S, 
8.56.
Synthesis of 5-(2-(4-chlorobenzyloxy)phenyl)-N-
substituted-1,3,4-thiadiazol-2-amine (10-16)
Concentrated sulfuric acid (10 mL) was added 
to the thiosemicarbazide compounds (3-9) (0.01 mol) 
A. A. Radwan, F. K. Alanazi, M. H. Al-Agamy
Braz. J. Pharm. Sci. 2017;53(1):e15239Page 4 / 12
with stirring at 0 °C. The reaction mixture was stirred 
for 3 h at room temperature, allowed to stand overnight, 
and neutralized with diluted sodium hydroxide. The 
precipitated crude solid was filtered and washed with 
water. The crude product was then recrystallized from 
a mixture of acetic acid and water (1:1 or 1:2) to yield 
disubstituted 1,3,4-thiadiazole (10-16).
5-(2-(4-chlorobenzyloxy)phenyl)-N-phenyl-1,3,4-
thiadiazol-2-amine (10)
Yield 3.35 g, 85%, melting point 154–156 °C; IR 
(KBr) 3278, 838, 751, 695 cm-1; 1H NMR (DMSOd6, δ 
ppm): 4.6 (s, 2H, Ar–CH2–O), 4.8–5.52 (bs, 1H, NH), 
6.94-7.69 (m, 13H, Ar-Hs). 13C NMR (DMSO-d6, δ ppm): 
70.42 (Ar–CH2–O), 117.69, 118.12, 122.1, 123.4, 125.2, 
126.4, 128.63, 128.85, 129.56, 130.18, 133.07, 133.25, 
135.93, 139.97, 154.05, 150.1, 169.04. Anal. calcd. for 
C21H16ClN3OS: C, 64.03; H, 4.09; N, 10.67; S, 8.14. 
Found: C, 63.88; H, 4.15; N, 10.51; S, 8.06.
5-(2-(4-chlorobenzyloxy)phenyl)-N-allyl-1,3,4-
thiadiazol-2-amine (11)
Yield 2.67 g, 75%, melting point 142–144 °C; IR 
(KBr) 3305, 883, 752, 672 cm-1; 1H NMR (DMSOd6, 
δ ppm): 4.36 (s, 2H, CH2=CH-CH2-), 4.92 (s, 2H, Ar–
CH2–O), 5.11 (d, 1H, J=10, transCH2=CH-), 5.16 (d, 
1H, J=17, cisCH2=CH-), 5.67 (m, 1H, CH2=CH-CH2-), 
5.8–6.34 (bs, 1H, NH), 7.13–7.72 (8H, m, Ar-Hs). 13C NMR 
(DMSO-d6, δ ppm): 45.86 (allyl-CH2), 69.17 (Ar–CH2–O), 
114.23, 116.04, 121.25, 122.4, 128.05, 128.6, 129.1, 129.42, 
133.62, 134.83, 139.65, 157.02, 164.3, 168.06. Anal. calcd. 
for C18H16ClN3OS: C, 60.41; H, 4.51; N, 11.74; S, 8.96. 
Found: C, 60.28; H, 4.64; N, 11.61; S, 8.82.
5-(2-(4-chlorobenzyloxy)phenyl)-N-m-tolyl-1,3,4-
thiadiazol-2-amine (12)
Yield 3.33 g, 82%, melting point 143–145 °C; IR 
(KBr) 3319, 884, 791, 697 cm-1; 1H NMR (DMSOd6, 
δ ppm): 2.31 (s, 3H, CH3), 4.95 (s, 2H, Ar–CH2–O), 
5.61–6.37 (bs, 1H, NH), 7.15–7.68 (m, 12H, Ar-Hs). 
13C NMR (DMSO-d6, δ ppm): 23.02 (CH3), 70.16 (Ar–
CH2–O), 112.61, 114.52, 118.3, 119.22, 120.81, 121.65, 
126.41, 127.91, 128.86, 129.32, 130.66, 131.54, 138.62, 
139.35, 141.55, 150.11, 155.54, 167.31. Anal. calcd. 
for C22H18ClN3OS: C, 64.78; H, 4.45; N, 10.30; S, 7.86. 
Found: C, 64.62; H, 4.42; N, 10.38; S, 7.78.
5-(2-(4-chlorobenzyloxy)phenyl)-N-p-tolyl-1,3,4-
thiadiazol-2-amine (13)
Yield 3.25 g, 80%, melting point 154–156 °C; IR 
(KBr) 3318, 819, 762, 684 cm-1; 1H NMR (DMSOd6, δ 
ppm): 2.38 (s, 3H, CH3), 5.13 (s, 2H, Ar–CH2–O), 5.74–
6.51 (bs, 1H, NH), 7.26–7.81 (m, 12H, Ar-Hs). 13C NMR 
(DMSO-d6, δ ppm): 21.32 (CH3), 69.75 (Ar–CH2–O), 
113.06, 114.32, 116.01, 118.98, 120.01, 120.89, 123.98, 
125.88, 128.31, 131.01, 133.05, 134.87, 135.92, 138.33, 
146.01, 151.04, 168.03. Anal. calcd. for C22H18ClN3OS: 
C, 64.78; H, 4.45; N, 10.30; S, 7.86. Found: C, 64.71; H, 
4.48; N, 10.26; S, 7.95.
5-(2-(4-chlorobenzyloxy)phenyl)-N-o-tolyl-1,3,4-
thiadiazol-2-amine (14)
Yield 3.0 g, 75%, melting point 146–148 °C; IR 
(KBr) 3299, 846, 749, 669 cm-1; 1H NMR (DMSOd6, δ 
ppm): 2.26 (s, 3H, CH3), 5.08 (s, 2H, Ar–CH2–O), 5.82–
6.38 (bs, 1H, NH), 7.02–7.73 (m, 12H, Ar-Hs). 13C NMR 
(DMSO-d6, δ ppm): 18.58 (CH3), 70.04 (Ar–CH2–O), 
113.46, 114.52, 114.89, 116.04, 116.53, 121.08, 124.05, 
125.12, 127.81, 130.76, 132.65, 133.65, 137.53, 138.09, 
149.31, 152.3, 166.14. Anal. calcd. for C22H18ClN3OS: 
C, 64.78; H, 4.45; N, 10.30; S, 7.86. Found: C, 64.76; H, 
4.51; N, 10.38; S, 7.72.
5-(2-(4-chlorobenzyloxy)phenyl)-N-(3-chlorophenyl)-
1,3,4-thiadiazol-2-amine (15)
Yield 3.33 g, 78%, melting point 150–152 °C; IR 
(KBr) 3296, 861, 788, 681 cm-1; 1H NMR (DMSOd6, δ 
ppm): 5.16 (s, 2H, Ar–CH2–O), 5.48–6.28 (bs, 1H, NH), 
7.23–7.84 (m, 12H, Ar-Hs). 13C NMR (DMSO-d6, δ ppm): 
70.33 (Ar–CH2–O), 112.35, 114.58, 116.25, 116.63, 
120.02, 122.87, 126.25, 126.91, 128.36, 130.57, 130.22, 
136.35, 138.39, 146.24, 151.05, 166.08. Anal. calcd. for 
C21H15Cl2N3OS: C, 58.89; H, 3.53; N, 9.81; S, 7.49. Found: 
C, 58.81; H, 3.42; N, 9.93; S, 7.59.
5-(2-(4-chlorobenzyloxy)phenyl)-N-isopropyl-1,3,4-
thiadiazol-2-amine (16)
Yield 2.65 g, 74%, melting point 156–158 °C; IR 
(KBr) 3295, 873, 775, 693 cm-1; 1H NMR (DMSOd6, δ 
ppm): 1.13 (d, 6H, J=6, 2CH3), 4.48 (m, 1H, CH), 5.08 (s, 
2H, Ar–CH2–O), 5.62–6.51 (bs, 1H, NH), 7.11–7.69 (m, 
8H, Ar-Hs). 13C NMR (DMSO-d6, δ ppm): 21.66 (CH3), 
46.8 (>CH), 69.04 (Ar–CH2–O), 113.31, 114.12, 114.01, 
118.42, 119.09, 120.96, 124.14, 124.54, 127.33, 128.97, 
133.12, 133.88, 137.63, 148.01, 151.11, 167.13. Anal. 
calcd. for C18H18ClN3OS: C, 60.07; H, 5.04; N, 11.68; S, 
8.91. Found: C, 60.11; H, 5.17; N, 11.61; S, 8.82.
Synthesis of 5-(2-(4-chlorobenzyloxy)phenyl)-4-
substituted-2H-1,2,4-triazole-3(4H)-thione (17-23)
Each of the thiosemicarbazides (3-9) (0.01 mol) 
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was dissolved in ethanol (200 mL). Then, 20 mL of an 
ethanolic solution of KOH (0.85 g, KOH, 0.015 mol) was 
added and the mixture was heated under reflux at 80 °C 
for 4 h. Excess ethanol was evaporated to dryness and the 
bulk of the solid was washed with 2 M hydrochloric acid, 
filtered, dried, and recrystallized from ethanol to yield the 
corresponding compounds (17-23).
5-(2-(4-chlorobenzyloxy)phenyl)-4-phenyl-2H-1,2,4-
triazole-3(4H)-thione (17)
Yield 3.25 g, 83%, melting point 223–225 °C; IR 
(KBr) 3315, 871, 752, 699 cm-1; 1H NMR (DMSOd6, 
δ ppm): 3.38 (bs, 1H, SH), 4.89 (s, 2H, Ar–CH2–O), 
6.91–7.51 (m, 13H, Ar-Hs). 13C NMR (DMSO-d6, δ ppm): 
69.04 (Ar–CH2–O), 113.1, 115.74, 122.24, 128.2, 128.28, 
129.02, 129.32, 129.51, 132.33, 132.9, 132.96, 134.57, 
135.92, 149.76, 156.35 (C5), 168.04 (C3). Anal. calcd. 
for C21H16ClN3OS: C, 64.03; H, 4.09; N, 10.67; S, 8.14. 
Found: C, 63.92; H, 4.13; N, 10.52; S, 8.23.
5-(2-(4-chlorobenzyloxy)phenyl)-4-allyl-2H-1,2,4-
triazole-3(4H)-thione (18)
Yield 2.65 g, 74%, melting point 231–233 °C; IR 
(KBr) 3308, 873, 756, 663 cm-1; 1H NMR (DMSOd6, 
δ ppm): 3.25 (bs, 1H, SH), 4.47 (d, 2H, J=5, CH2=CH-
CH2-), 4.7 (d, 1H, J=17, transCH2=CH-), 4.95 (d, 1H, 
J=10 cisCH2=CH-), 5.19 (s, 2H, Ar–CH2–O), 5.62 (m, 
1H, CH2=CH-CH2-), 7.08–7.57 (m, 8H, Ar-Hs). 13C 
NMR (DMSO-d6, δ ppm): 69.04 (Ar–CH2–O), 46.06 
(Allyl-CH2), 69.14 (Ar–CH2–O), 113.59, 115.83, 117.31, 
124.13, 128.97, 129.78, 132.02, 132.18, 133.08, 133.1, 
135.94, 149.73, 156.62 (C5), 167.18 (C3). Anal. calcd. 
for C18H16ClN3OS: C, 60.41; H, 4.51; N, 11.74; S, 8.96. 
Found: C, 60.32; H, 4.59; N, 11.66; S, 9.08.
5-(2-(4-chlorobenzyloxy)phenyl)-4-(m-tolyl)-2H-1,2,4-
triazole-3(4H)-thione (19)
Yield 3.0 g, 73%, melting point 185–187 °C; IR 
(KBr) 3293, 871, 787, 693 cm-1; 1H NMR (DMSOd6, 
δ ppm): 2.14 (s, 3H, CH3), 4.15 (bs, 1H, SH), 4.87 (s, 
2H, Ar–CH2–O), 6.83–7.45 (m, 12H, Ar-Hs). 13C NMR 
(DMSO-d6, δ ppm): 21.17 (CH3), 69.12 (Ar–CH2–O), 
113.06, 116.98, 121.15, 125.03, 128.55, 128.75, 128.82, 
129.24, 132.37, 132.41, 134.76, 135.34, 136.16, 138.04, 
149.51, 156.29 (C5), 166.38 (C3). Anal. calcd. for 
C22H18ClN3OS: C, 64.78; H, 4.45; N, 10.30; S, 7.86. 
Found: C, 64.61; H, 4.52; N, 10.23; S, 7.94.
5-(2-(4-chlorobenzyloxy)phenyl)-4-(p-tolyl)-2H-1,2,4-
triazole-3(4H)-thione (20)
Yield 3.1 g, 76%, melting point 177–179 °C; IR 
(KBr) 3308, 872, 809, 754 cm-1; 1H NMR (DMSOd6, 
δ ppm): 2.26 (s, 3H, CH3), 3.7 (bs, 1H, SH), 4.84 (s, 
2H, Ar–CH2–O), 6.84–7.38 (m, 12H, Ar-Hs). 13C NMR 
(DMSO-d6, δ ppm): 21.14 (CH3), 69.83 (Ar–CH2–O), 
113.04, 119.15, 121.01, 127.12, 128.7, 128.79, 129.38, 
131.31, 132.29, 132.62, 134.53, 135.39, 136.7, 149.31, 
156.01 (C5), 167.81 (C3). Anal. calcd. for C22H18ClN3OS: 
C, 64.78; H, 4.45; N, 10.30; S, 7.86. Found: C, 64.72; H, 
4.58; N, 10.41; S, 7.73.
5-(2-(4-chlorobenzyloxy)phenyl)-4-(o-tolyl)-2H-1,2,4-
triazole-3(4H)-thione (21)
Yield 2.9 g, 70%, melting point 200–202 °C; IR 
(KBr) 3311, 810, 754, 719 cm-1; 1H NMR (DMSOd6, δ 
ppm): 1.99 (s, 3H, CH3), 3.49 (bs, 1H, SH), 5.0 (s, 2H, Ar–
CH2–O), 6.89–7.42 (m, 12H, Ar-Hs). 13C NMR (DMSO-d6, 
δ ppm): 18.17 (CH3), 69.51 (Ar–CH2–O), 113.17, 120.91, 
126.4, 128.36, 129.12, 129.38, 129.43, 130.36, 132.01, 
132.37, 132.79, 134.98, 136.2, 136.64, 149.33, 156.47 
(C5), 166.86 (C3). Anal. calcd. for C22H18ClN3OS: C, 
64.78; H, 4.45; N, 10.30; S, 7.86. Found: C, 64.71; H, 
4.36; N, 10.39; S, 7.72.
5-(2-(4-chlorobenzyloxy)phenyl)-4-(m-chlorophenyl)-
2H-1,2,4-triazole-3(4H)-thione (22)
Yield 3.5 g, 84%, melting point 225–226 °C; IR 
(KBr) 3327, 858, 776, 684 cm-1; 1H NMR (DMSOd6, δ 
ppm): 4.26 (bs, 1H, SH), 5.01 (s, 2H, Ar–CH2–O), 7.08–
7.61 (m, 12H, Ar-Hs). 13C NMR (DMSO-d6, δ ppm): 70.29 
(Ar–CH2–O), 112.22, 118.64, 124.31, 125.01, 127.54, 
128.12, 129.26, 131.47, 131.16, 132.22, 133.06, 135.18, 
138.01, 148.31, 158.32 (C5), 169.11 (C3). Anal. calcd. for 
C21H15Cl2N3OS: C, 58.89; H, 3.53; N, 9.81; S, 7.49. Found: 
C, 58.72; H, 3.58; N, 9.73; S, 7.58.
5-(2-(4-chlorobenzyloxy)phenyl)-4-(isopropyl)-2H-
1,2,4-triazole-3(4H)-thione (23)
Yield 2.7 g, 75%, melting point 212–213 °C; IR 
(KBr) 3328, 871, 809, 755 cm-1; 1H NMR (DMSOd6, δ 
ppm): 1.17 (d, 6H, J=6, 2CH3), 4.25 (m, 1H, CH), 4.06 
(bs, 1H, SH), 5.28 (s, 2H, Ar–CH2–O), 6.72–7.65 (m, 
8H, Ar-Hs). 13C NMR (DMSO-d6, δ ppm): 23.18 (CH3), 
42.86 (>CH), 69.84 (Ar–CH2–O), 113.34, 116.81, 121.05, 
125.35, 127.67, 128.33, 129.14, 130.45, 136.16, 132.68, 
133.06, 136.18, 139.01, 141.52, 152.08 (C5), 166.63 (C3). 
Anal. calcd. for C18H18ClN3OS: C, 60.07; H, 5.04; N, 
11.68; S, 8.91. Found: C, 59.91; H, 5.11; N, 11.62; S, 8.88.
Anti-Candida albicans screening
The initial screening of antifungal activity and 
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determination of minimum inhibitory concentration (MIC) 
for different synthetic compounds were performed using 
the cup plate diffusion method and macro-broth dilution 
method, respectively (Bauer et al., 1966; Arendrup et al., 
2012).
Cup plate experiment
Three to five pure colonies of Candida albicans 
ATCC 2091 were taken from overnight culture of 
Sabauraud’s 2% dextrose agar medium (Merck®, 
Darmstadt, Germany) and suspended in 5 mL of 
Sabauraud’s 2% dextrose broth medium. The inoculum 
was evenly suspended by vigorous shaking on a vortex 
mixer for 15 s. The yeast strain was measured using 
a spectrophotometer (LKB® Ultrospec) at 530 nm to 
give absorbance of 0.2-0.15 (1-5x106 CFU/mL). The 
suspension was diluted 1:10 in Sabauraud’s 2% dextrose 
broth medium to obtain 1x105 CFU/mL. The suspension 
was swabbed onto a Sabauraud’s 2% dextrose agar plate 
and allowed to dry completely. Three ditches per agar plate 
were made using a cork borer. Then, 100 µL (512 µg) of 
stock solution (5120 µg mL-1) was transferred into the 
cup using a sterile pipette. The plates were refrigerated at 
4°C for 30 min for diffusion, and then incubated at 37°C 
for 24 h. After the incubation period, the diameter of the 
inhibition zone (including the diameter cup) was measured 
and recorded in mm. Fluconazole (50 µg mL-1) was used as 
a positive control. The assay was carried out in duplicate.
Determination of MIC
MIC was determined with the broth dilution 
method. The test solution and all standard drugs were 
prepared at a concentration of 2048 μg mL-1 in distilled 
dimethylsulfoxide and treated as stock solutions. Briefly, 
1 mL of RPMI 1640 medium was dispensed into a sterile 
7 mL bijou tube (Sterilin Limited, UK). Ten tubes were 
required for each experiment and each experiment 
was done in duplicate. Tubes #9 and #10 were used 
as the positive growth control (no tested compound) 
and the negative control for the medium sterility (no 
microorganism), respectively. A 1-mL (2048 μg mL-1) 
aliquot of the tested compound was pipetted into tube #1 
and mixed well for a concentration of 1024 μg mL-1. Then, 
1 mL was transferred from tube #1 to tube #2 for a twofold 
dilution (512 μg mL-1). This procedure was repeated down 
to tube #8, for a concentration of 8 μg mL-1 in tube #8. 
One milliliter was discarded from tube #8. Then, 1 mL 
of inoculum (1-5x105 CFU/mL) was added to each of the 
eight tubes to give a final concentration of 0.5-2.5x105 
CFU/mL and to make a two-fold dilution of the tested 
compound. In addition, tube #9 (growth control tube), 
containing 1 mL of sterile drug-free distilled water, was 
inoculated with 1 mL of the same inoculum suspension. 
One milliliter of drug-free medium was added to tube 
#10 as a sterility control for medium. The inoculated 
tubes were incubated at 35°C for 20 h. The tubes were 
inoculated with prepared yeast suspension within 30 min 
in order to maintain the viable cell concentration. After 
the incubation period, the results of MIC were recorded 
manually and interpreted according to the guidelines of 
the European Committee for Antimicrobial Susceptibility 
Testing (EUCAST).
Docking procedure
The docking studies were performed on a PC with 
Windows Vista Home Premium Intel(R) Core(TM)2 Duo, 
1.83GHz using Autodock vina program (Trott, Olson, 
2010). The chemical structures of the compounds under 
study were prepared with a protonation state similar to that 
found under physiological conditions. The X-ray crystal 
structure of the 14-α-sterol demethylase (CYP51) enzyme 
complexed with fluconazole (1EA1) was obtained from 
the Protein Data Bank (Podust, Poulos, Waterman, 2001). 
The cocrystallized fluconazole structure was docked in 
its target macromolecule structure using Autodock vina 
program with its default settings.
RESULTS AND DISCUSSION
Chemistry
M e t h y l  2 - ( 4 - c h l o r o b e n z y l o x y ) b e n z o a t e 
(1) was synthesized through the reaction of methyl 
2-hydroxybenzoate with p-chlorobenzyl chloride. Reaction 
of 1 and hydrazine hydrate yielded the corresponding 
hydrazide (2). Reaction of 2 with the corresponding 
isothiocyanate yielded the isothiocyanate derivatives 
(3-9), which were cyclized in concentrated sulfuric 
acid resulting in 1,3,4-thiadiazoles (10-16) (Daoud, Al-
Obaydi, 2008). The reflux of 2 in 2 M NaOH yielded 
the corresponding 1,3,4-triazole-2-thione derivatives 
(17-23) (Daoud, Al-Obaydi, 2008). The synthetic 
route of these compounds is given in the scheme. The 
chemical structures of the synthesized compounds were 
in accordance with their 1H and 13C NMR spectra. The 
spectral data are summarized in the material and methods 
section. 1H NMR and 13C NMR spectra were measured 
in dimethylsulfoxide-d6 for compounds 2-23 at ambient 
temperature. 1H NMR spectrum of compound 2 showed 
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a characteristic signal at δ 5.24 ppm corresponding to the 
methylene protons of the p-chlorobenzyloxy moiety. The 
disappearance of the methyl ester signal and appearance 
of two signals at δ 4.53 and 9.24 exchangeable with 
deuterium oxide are consistent with the chemical structure 
of the hydrazide derivative 2. 1H NMR and 13C NMR 
spectra of the thiosemicarbazide compounds 3–9 showed 
a similar trend in the chemical shift of the common part 
of the molecular backbone. In the 1H NMR spectra, the 
presence of a singlet at δ 5.24-5.32 ppm was assigned to 
the methylene protons of the p-chlorobenzyloxy moiety, 
and the three singlets exchangeable with deuterium 
oxide at δ 9.15-9.52, 9.48-10.04, and 10.09-10.18 ppm 
were assigned to the thiosemicarbazide NH protons. 
The 13C-NMR spectra showed characteristic signals at 
δ 69.37–69.7, 165.02-165.78, and 180.76-182.23 ppm 
due to the methylene carbon of the p-chlorobenzyloxy 
substituent, C=O, and C=S, respectively. The 1H NMR and 
13C NMR spectra of the triazole compounds 10-16 were 
characterized by the absence of the amide and thioamide 
signals. In the 1H NMR spectra, the methylene protons of 
the p-chlorobenzyloxy moiety resonated at δ 4.6-5.16 ppm. 
In compound 11, the allyl substituent showed a singlet at 
δ 4.36 due to an allylic methylene, a doublet at δ 5.11, a 
doublet at δ 5.16 due to trans and cis protons of vinylic 
methylene, and a multiplet at 5.67 due to vinylic methine. 
In compounds 12-14, the methyl protons of tolyl groups 
resonated at δ 2.31, 2.38, and 2.26 ppm, respectively. In 
compound 16, two characteristic signals of the isopropyl 
group appeared as a doublet at δ 1.13 and a multiplet at δ 
4.48. In the 13C NMR spectra, the methylene carbon of the 
p-chlorobenzyloxy substituent resonated at δ 69.04-70.42 
ppm while the C-2 and C-5 of the thiadiazole ring resonated 
at δ 150.1-157.02 and 164.3-169.04 ppm, respectively. The 
1H NMR and 13C NMR spectra of the triazole compounds 
17-23 showed two singlets at δ 3.25-4.26 and 4.47-5.28 
ppm due to the SH and methylene protons, respectively, of 
the p-chlorobenzyloxy substituent. In addition, the methyl 
protons of the tolyl moiety in compounds 19-21 resonated 
at δ 2.14, 2.26, and 1.99 ppm, respectively. Compound 
23 showed two additional characteristic signals of the 
isopropyl group as a doublet at δ 1.17 and a multiplet 
SCHEME - Synthetic pathway of compounds 1-23.
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at δ 4.25 ppm. In the 13C NMR spectra, the methylene 
carbon of the p-chlorobenzyloxy substituent resonated at 
δ 69.04-70.29 ppm, while the C-2 and C-5 of the triazole 
ring resonated at δ 166.38-169.11 and 152.08-158.32 ppm, 
respectively.
Anti-Candida albicans screening 
Fluconazole has been widely used for treatment of 
fungal infections, but its extensive clinical use has led to the 
development of drug resistance (Pfaller et al., 2010). The 
in vitro anti-candida activity of the synthesized compounds 
3-23 was evaluated against C. albicans. The obtained 
data, expressed as the diameter of the inhibition zone 
(DIZ) and minimum inhibition concentration (MIC) for 
the test compounds and for the reference drug fluconazole 
are presented in Table I. Compounds 3-9 were found to 
be inactive against C. albicans, while compounds 10-23 
showed promising antifungal activity with DIZ = 13–18 
mm towards C. This suggests that the cyclization of the 
biologically inactive thiosemicarbazides 3-9 into thiadiazole 
or triazole rings developed biologically active compounds 
against C. albicans at a concentration of 100 µg mL-1. In 
other words, the heterocyclic ring in these compounds 
is crucial for their antifungal activity. Compounds 10-23 
showed MIC values in the range of 0.08-0.17 µmol mL-1, 
while the MIC value of fluconazole was 0.052 µmol mL-1. 
Compounds 11 and 18 were found to be the most active, 
with MIC values of 0.08 µmol mL-1. The allyl substituent 
at position 4 of the heterocyclic ring showed higher activity 
than the phenyl, tolyl, or isopropyl substituents. Basically, 
the small bulk size of the allyl group is proposed to be related 
to the high activity of the compound. For optimization of 
antifungal activity and in view of these results, further 
studies will be suggested to be undertaken starting with the 
two lead compounds 11 and 18.
TABLE I - AntiCandida albicans activity of compounds 10-23 (100 μg mL-1)
  
Compd. no. R DIZ (mm)* MIC (µmol mL-1)**
10 Phenyl 12 0.16
11 Allyl 16 0.08
12 m-Tolyl 13 0.15
13 p-Tolyl 12 0.15
14 o-Tolyl 12 0.15
15 3-Chlorophenyl 13 0.14
16 Isopropyl 13 0.17
17 Phenyl 12 0.17
18 Allyl 18 0.08
19 m-Tolyl 13 0.15
20 p-Tolyl 14 0.15
21 o-Tolyl 14 0.15
22 3-Chlorophenyl 13 0.14
23 Isopropyl 13 0.17
Fluconazol - 18 0.05
 * The arithmetic mean of the inhibition zone diameters in mean ± standard deviation. **The lowest concentration of the compound 
that produced 50-80% microbial growth inhibition (μmol mL-1). Count=14, Mean=0.3, Standard Devation= 0.029, Standard 
Error=0.008, Sample Variance=0.001.
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Docking Procedure
The comparative study of the binding mode of the 
synthesized compounds and the drug fluconazole with the 
binding site of the CYP51 protein was done using Autodock 
vina (Trott, Olson, 2010). From the protein data bank, the 
X-ray structure of the enzyme bound with fluconazole 
(FCZ) was obtained; PDB code: 1EA1 (Podust, Poulos, 
Waterman, 2001). The docking procedure was confirmed 
based on the RMSD value difference of 0.432 Å of the pose 
of the nonrestricted redocked FCZ into the binding site of 
the CYP51 from the co-crystallized FCZ (Figure 1). The 
binding domain shows a hydrophobic pocket surrounded 
by the side chains of Tyr 76, Phe 78, Met 79, Phe 83, Arg 
96, Met 99, Leu 100, Ser 252, Met 253, Phe 255, Ala 256, 
His 259, Thr 260, Leu 321, Ile 323, Met 433, and Val 434 
(Figure 2). The docking results of compound 18 revealed 
that its triazole ring occupied the same position inside the 
binding site and showed the same orientation as the triazole 
moiety of the co-crystallized FCZ with 1EA1 (Figure 2). 
The triazole ring is oriented near the heme molecule inside 
the binding domain and is surrounded by the side chains of 
Phe 255, Ala 256, His 259, and Thr 260. The p-chlorophenyl 
moiety overlaid the second triazole ring FCZ, showing 
hydrophobic interaction with the side chains of Leu 321, Ile 
323, Met 433, and Val 434. In addition, the allyl substituent 
is oriented in the same binding pocket of the difluorophenyl 
moiety of FCZ, showing hydrophobic interaction with the 
side chains of Phe 83, Arg 96, Met 99, Leu 100, Ser 252, 
and Met 253.
CONCLUSION
A novel series of thiosemicarbazide derivatives 
of methyl o-chlorobenzylysalicylate and its cyclized 
forms, 1,3,4-thiadiazol-2-amine and 2H-1,2,4-triazole-
3(4H)-thione, has been synthesized and screened for 
FIGURE 1 - The co-crystallized fluconazol FCZ (from 1EA1.
pdb, colored cyan) overlaid onto the redocked fluconazol 
(colored magenta).
FIGURE 2 - The 3D diagram showing the interaction between the 1EA1.pdb structure and compound 18 (sticks, blue) overlaid on 
fluconazol FCZ x-ray ligand (stick, orange).
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anti-Candida albicans activity. Variable and promising 
anti-Candida albicans activity was observed in the 
synthesized compounds 10-23; these compounds had MIC 
values in the range of 0.08-0.17 µmol mL-1, while the MIC 
value of fluconazole was 0.05 µmol mL-1. Compounds 
11 and 18 were found to be the most active, with MIC 
values of 0.08 µmol mL-1. In addition, an in silico docking 
study of compound 18 with X-ray structure of 14-α-sterol 
demethylase (CYP51) active site domain (1EA1) 
postulated that the designed compound may act on the 
same enzyme target as the fluconazole x-ray structure. A 
good correlation was found between the in silico generated 
model and the reported X-ray structure, with similar 
hydrogen bonding and orientation inside the binding site.
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